- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04031066
Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis (SHAMAN)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis
Randomized, double-blind, placebo-controlled, parallel group study where subjects will receive velmanase alfa or placebo for 24 weeks.
Each subject undergoes to 8 complete visits at the clinic for clinical, laboratory and functional assessments. Study treatment is administered weekly through i.v. infusions
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
A Screening visit (V1) will take place 7±3 days prior to randomization in order to give the subject enough time to consider their participation in the study, to plan the next visits including the long-stay visits at V2, V5 and V8 (long-stay visits as PK and certain tests are performed over more than one day), and to allow the clinic center to complete the evaluation of the eligibility criteria.
Upon confirmation of eligibility, subjects will be randomized to receive weekly i.v. administration of either velmanase alfa 1 mg/kg or placebo.
Thereafter, subjects will undergo weekly visits for administration of study treatment and safety data collection. Clinical, laboratory and functional assessments will be performed at the 4-weekly assessment visits with each subject undergoing a minimum of 8 assessment visits (V1 to V8).
Study Type
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed diagnosis of alpha-mannosidosis based on alpha mannosidase activity <10% of normal in leukocytes or fibroblasts or through genetic testing;
- Capability to comply with the protocol;
- Evidence of informed consent provided by subject or legally authorized guardian(s) prior to performance of any trial-related activities.
Exclusion Criteria:
- Previous hematopoietic stem cells transplantation (HSCT) with positive outcome;
- Major surgery planned within 3 months prior to study entry or planned during the study that, in the opinion of the Investigator, would preclude participation in the trial;
- Known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical condition that would preclude participation in the study in the Investigator's judgment;
- Pregnant (as evident by a positive urine hCG or serum-hCG test) or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential [WOCBP]) UNLESS they are willing to use highly effective birth control methods;
- Participation in other interventional trials testing investigational medicinal products (IMPs) within the last 6 months;
- Total IgE >800 IU/ml;
- Any hypersensitivity to velmanase alfa or its excipients that, in the judgment of the Investigator, places the subject at an increased risk for adverse reactions
- Clinically active infection and recent vaccinations (within the last month before screening).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
infusion i.v. treatment
|
Experimental: Velmanase alfa
|
infusion i.v. treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in concentration of serum oligosaccharides
Time Frame: 24 weeks (end of study)
|
To evaluate the efficacy of velmanase alfa compared with placebo after 24 weeks of velmanase alfa treatment as measured by Level of serum oligosaccharides;
|
24 weeks (end of study)
|
Change in serum level of total immunoglobulin (Ig)G level
Time Frame: 24 weeks (end of study)
|
Efficacy of velmanase alfa compared with placebo in alpha mannosidosis subjects based on serum levels of total immunoglobulin (Ig)G after 24 weeks of velmanase alfa treatment
|
24 weeks (end of study)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Intracellular level of oligosaccharides in peripheral blood leukocytes
Time Frame: 24 weeks (end of study)
|
To evaluate the efficacy of velmanase alfa compared with placebo after 24 weeks of velmanase alfa treatment as measured by Intracellular level of oligosaccharides accumulated in peripheral blood leukocytes.
|
24 weeks (end of study)
|
Change in serum IgG Subclasses
Time Frame: 24 weeks (end of study)
|
To evaluate the efficacy of velmanase alfa compared with placebo after 24 weeks of velmanase alfa treatment as measured by Subclasses of IgG;
|
24 weeks (end of study)
|
Incidence of Infections
Time Frame: 24 weeks (end of study)
|
Change in number of infections requiring antibiotics and/or hospitalization and/or loss of school/working days
|
24 weeks (end of study)
|
Assessment of PK parameter Maximum plasma Concentration [Cmax]
Time Frame: 12 weeks
|
To collect additional data on Cmax profile following velmanase alfa treatment
|
12 weeks
|
Assessment of PK parameter Maximum plasma Concentration [Cmax]
Time Frame: 24 weeks (end of study)
|
To collect additional data on Cmax profile following velmanase alfa treatment
|
24 weeks (end of study)
|
Assessment of PK parameter Area Under the Curve [AUC]
Time Frame: 24 weeks (end of study)
|
To collect additional data on AUC profile following velmanase alfa treatment
|
24 weeks (end of study)
|
Assessment of PK parameter Area Under the Curve [AUC]
Time Frame: 12 weeks
|
To collect additional data on AUC profile following velmanase alfa treatment
|
12 weeks
|
Assessment of PK parameter Elimination half-life [t1/2]
Time Frame: 12 weeks
|
To collect additional data on t1/2 profile following velmanase alfa treatment
|
12 weeks
|
Assessment of PK parameter Elimination half-life [t1/2]
Time Frame: 24 weeks (end of study)
|
To collect additional data on t1/2 profile following velmanase alfa treatment
|
24 weeks (end of study)
|
Assessment of PK parameter trough concentration (Ctrough)
Time Frame: 12 weeks
|
To collect additional data on Ctrough profile following velmanase alfa treatment
|
12 weeks
|
Assessment of PK parameter trough concentration (Ctrough)
Time Frame: 24 weeks (end of study)
|
To collect additional data on Ctrough profile following velmanase alfa treatment
|
24 weeks (end of study)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (AEs)
Time Frame: 24 weeks (end of study)
|
Number of AEs will be described for each patient and cumulatively in the safety population
|
24 weeks (end of study)
|
Infusion Related Reactions (IRRs)
Time Frame: 24 weeks (end of study)
|
Number of IRRs will be described for each patient and cumulatively in the safety population
|
24 weeks (end of study)
|
Incidence of Adverse Drug Reactions (ADRs)
Time Frame: 24 weeks (end of study)
|
Number of ADRs will be described for each patient and cumulatively in the safety population
|
24 weeks (end of study)
|
Anty-Drug Antibody (ADA) level
Time Frame: 24 weeks (end of study)
|
Change in ADA will be described for each patient and cumulatively in the safety population
|
24 weeks (end of study)
|
Neutralizing Antibody (NAb) level
Time Frame: 24 weeks (end of study)
|
Change in NAb levels will be described for each patient and cumulatively in the safety population
|
24 weeks (end of study)
|
Change on Immunoglobuline Type A (IgA) values
Time Frame: 24 weeks (end of study)
|
Change in IgA levels will be described for each patient and cumulatively in the safety population
|
24 weeks (end of study)
|
Change on Immunoglobuline Type M (IgM) values
Time Frame: 24 weeks (end of study)
|
Change in IgM levels will be described for each patient and cumulatively in the safety population
|
24 weeks (end of study)
|
Change on B-cell immunophenotype level
Time Frame: 24 weeks (end of study)
|
Change in B-cell immunophenotype levels will be described for each patient and cumulatively in the safety population
|
24 weeks (end of study)
|
3MSCT (3-Minute Stair Climb Test)
Time Frame: 24 weeks (end of study)
|
Change from baseline in motricity tests (climbing test) will be described for each patient
|
24 weeks (end of study)
|
6MWT (2MWT for children) (6- or 2-Minute Walk Test)
Time Frame: 24 weeks (end of study)
|
Change from baseline in motricity tests (walking test) will be described for each patient
|
24 weeks (end of study)
|
FVC, FEV1 and PEF
Time Frame: 24 weeks (end of study)
|
Change from baseline in respiratory tests (Spirometry) will be described for each patient
|
24 weeks (end of study)
|
Psychotic events
Time Frame: 24 weeks (end of study)
|
Change from baseline in number of psychotic events will be described for each patient
|
24 weeks (end of study)
|
Shoulder mobility
Time Frame: 24 weeks (end of study)
|
Change from baseline in shoulder mobility will be described for each patient
|
24 weeks (end of study)
|
ECG PR interval
Time Frame: 24 weeks (end of study)
|
Change from baseline in electrocardiogram (ECG) PR interval will be described for each patient
|
24 weeks (end of study)
|
ECG QT interval
Time Frame: 24 weeks (end of study)
|
Change from baseline in electrocardiogram (ECG) QT interval will be described for each patient
|
24 weeks (end of study)
|
ECG QRS duration
Time Frame: 24 weeks (end of study)
|
Change from baseline in electrocardiogram (ECG) QRS duration will be described for each patient
|
24 weeks (end of study)
|
Heart diseases
Time Frame: 24 weeks (end of study)
|
Change from baseline in Echocardiogram will be described for each patient
|
24 weeks (end of study)
|
Hearing testing
Time Frame: 24 weeks (end of study)
|
Change from baseline in hearing testing through PTA will be described for each patient
|
24 weeks (end of study)
|
Kaufman-II (Kaurfman Assessment Battery for Children - 2nd Edition)
Time Frame: 24 weeks (end of study)
|
Change in score from baseline in cognitive testing Kaufman-II will be described for each patient
|
24 weeks (end of study)
|
Bayley-III (Bayley Scales of Infant and Toddler Development - 3rd Edition)
Time Frame: 24 weeks (end of study)
|
Change in score from baseline in cognitive testing Bayley-III will be described for each patient
|
24 weeks (end of study)
|
VABS-3 scores (Vineland Adaptive Behavior Scales - 3rd Edition)
Time Frame: 24 weeks (end of study)
|
Change in score from baseline in cognitive testing VABS-3 will be described for each patient
|
24 weeks (end of study)
|
Development Motor scale
Time Frame: 24 weeks (end of study)
|
Change from baseline in Peabody Delelopment Motor scale (PMDS-2) scores will be described for each patient
|
24 weeks (end of study)
|
EQ-5D-5L (European Quality of Life Five Dimension Five Level) Questionnaire
Time Frame: 24 weeks (end of study)
|
Change in score from baseline for questionnaire EQ-5D-5L will be described for each patient
|
24 weeks (end of study)
|
CHAQ (Childhood Health Assessment Questionnaire)
Time Frame: 24 weeks (end of study)
|
Change in score from baseline for CHAQ will be described for each patient
|
24 weeks (end of study)
|
MPS Health Assessment Questionnaire
Time Frame: 24 weeks (end of study)
|
Change in score from baseline for questionnaire MPS Health Assessment Questionnaire will be described for each patient
|
24 weeks (end of study)
|
Zarit Burden Interview
Time Frame: 24 weeks (end of study)
|
Change in score from baseline for questionnaire Zarit Burden Interview will be described for each patient
|
24 weeks (end of study)
|
CBCL (Child Behavioral Checklist) or ABCL (Adult Behavioral Checklist) according to age
Time Frame: 24 weeks (end of study)
|
Change in score from baseline for CBCL or ABCL will be described for each patient
|
24 weeks (end of study)
|
PEDI (Pediatric Evaluation of Disability Inventory)
Time Frame: 24 weeks (end of study)
|
Change in score from baseline for PEDI will be described for each patient
|
24 weeks (end of study)
|
PROMIS-SF (Patient-reported Outcomes Measurement Information System Short Forms)
Time Frame: 24 weeks (end of study)
|
Change in score from baseline for PROMIS-SF will be described for each patient
|
24 weeks (end of study)
|
Service-use and cost questionnaire to patient and families
Time Frame: 24 weeks (end of study)
|
Change in score from baseline will be described for each patient
|
24 weeks (end of study)
|
Physician's Judgement of Overall Response
Time Frame: 24 weeks (end of study)
|
Change from baseline based on a Likert scale (0 to 5)
|
24 weeks (end of study)
|
Caregiver's Judgement of Overall Response
Time Frame: 24 weeks (end of study)
|
Change from baseline based on a Likert scale (0 to 5)
|
24 weeks (end of study)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Paul Harmatz, MD, UCSF Benioff Children's Hospital Oakland
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLI-LMZYMAA2-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alpha-Mannosidosis
-
Zymenex A/SEuropean CommissionUnknown
-
Zymenex A/SEuropean CommissionCompleted
-
Zymenex A/SEuropean CommissionCompletedAlpha MannosidosisCzechia, Germany, Norway, United Kingdom
-
CENTOGENE GmbH RostockWithdrawnAlpha-Mannosidase B Deficiency | Lysosomal Alpha B Mannosidosis | Alpha-Mannosidase DeficiencyIndia, Sri Lanka, Germany
-
Chiesi Farmaceutici S.p.A.CompletedAlpha-MannosidosisFrance
-
Zymenex A/SEuropean CommissionCompletedA Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-MannosidosisAlpha-MannosidosisDenmark, United Kingdom, France, Germany, Poland
-
Chiesi Farmaceutici S.p.A.Not yet recruiting
-
Chiesi Farmaceutici S.p.A.CromsourceCompletedAlpha-MannosidosisFrance, Denmark, Austria, Germany, Italy
-
Chiesi Farmaceutici S.p.A.Completed
Clinical Trials on Velmanase Alfa
-
Chiesi Farmaceutici S.p.A.Not yet recruiting
-
Chiesi Farmaceutici S.p.A.CromsourceCompletedAlpha-MannosidosisFrance, Denmark, Austria, Germany, Italy
-
ShireCompleted
-
Jonsson Comprehensive Cancer CenterAmgenCompletedLymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Precancerous/Nonmalignant ConditionUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Clinical Affairs, L.L.C.TerminatedNeoplasms | Cancer | AnemiaUnited States
-
Philogen S.p.A.RecruitingCarcinoma, Basal Cell | Carcinoma, Cutaneous Squamous CellGermany, Poland, Switzerland
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With InhibitorsTaiwan, United Kingdom, Thailand, Serbia, Croatia, Italy, Poland, Romania, Hungary, Malaysia, United States, Austria, Brazil, Greece, Japan, Puerto Rico, Russian Federation, South Africa, Turkey
-
University of California, San FranciscoDuke UniversityRecruitingWolman Disease | MPS IVA | Pompe Disease Infantile-Onset | Gaucher Disease, Type 2 | MPS VI | MPS I | Gaucher Disease, Type 3 | MPS II | Mps VIIUnited States